Kogenate FS (Hemophilia A and B)：市場予測と分析（～2022）...市場調査レポートについてご紹介

1 Table of Contents
1 Table of Contents 5
1.1 List of Tables 7
2 Introduction 8
2.1 Catalyst 8
2.2 Related Reports 9
2.3 Upcoming Related Reports 11
3 Disease Overview 12
3.1 Etiology and Pathophysiology 12
3.1.1 Etiology 12
3.1.2 Pathophysiology 13
3.1.3 Prognosis and Quality of Life 15
3.2 Symptoms 16
3.2.1 Hemophilia A and B 16
3.2.2 Inhibitors 17
4 Disease Management 18
4.1 Treatment Overview 18
4.1.1 Hemophilia A and B Diagnosis 19
4.1.2 Hemophilia A and B Treatment 19
4.1.3 Inhibitors Diagnosis 21
4.1.4 Inhibitors Treatment 21
5 Competitive Assessment 23
5.1 Overview 23
5.2 Strategic Competitive Assessment 24
6 Kogenate FS / Helixate FS (Antihemophilic Factor (Recombinant)) 28
6.1 Overview 28
6.2 Efficacy 30
6.3 Safety 30
6.4 SWOT Analysis 31
6.5 Forecast 31
7 Appendix 33
7.1 Bibliography 33
7.2 Abbreviations 36
7.3 Methodology 38
7.4 Forecasting Methodology 38
7.4.1 Diagnosed Hemophilia Patients 39
7.4.2 Percent Drug-Treated Patients 39
7.4.3 General Pricing Assumptions 39
7.4.4 Individual Drug Assumptions 40
7.5 About the Authors 43
7.5.1 Authors 43
7.6 About GlobalData 44
7.7 Disclaimer 44